TW200503689A - Pharmaceutical compositions of atorvastatin - Google Patents
Pharmaceutical compositions of atorvastatinInfo
- Publication number
- TW200503689A TW200503689A TW093116574A TW93116574A TW200503689A TW 200503689 A TW200503689 A TW 200503689A TW 093116574 A TW093116574 A TW 093116574A TW 93116574 A TW93116574 A TW 93116574A TW 200503689 A TW200503689 A TW 200503689A
- Authority
- TW
- Taiwan
- Prior art keywords
- atorvastatin
- compositions
- pharmaceutical compositions
- dry
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Abstract
A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Aizheimer's disease using a therapeutically effective amount of the pharmatceutical composition.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791703P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200503689A true TW200503689A (en) | 2005-02-01 |
Family
ID=33551780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093116574A TW200503689A (en) | 2003-06-12 | 2004-06-09 | Pharmaceutical compositions of atorvastatin |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635788A1 (en) |
JP (1) | JP2006527259A (en) |
KR (1) | KR100760112B1 (en) |
CN (1) | CN1805732A (en) |
AR (1) | AR044660A1 (en) |
AU (1) | AU2004246867A1 (en) |
BR (1) | BRPI0411354A (en) |
CA (1) | CA2465693A1 (en) |
CO (1) | CO5640071A2 (en) |
MX (1) | MXPA05012955A (en) |
NO (1) | NO20060149L (en) |
RU (1) | RU2325903C2 (en) |
TW (1) | TW200503689A (en) |
WO (1) | WO2004110406A1 (en) |
ZA (1) | ZA200508204B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007515430A (en) * | 2004-10-18 | 2007-06-14 | テバ ファーマシューティカル インダストリーズ リミティド | Method for preparing amorphous atorvastatin hemi-calcium by dissolving a salt in an organic solvent which is a mixture of alcohol and ketone and / or ester and removing the solvent |
CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
WO2007111027A1 (en) * | 2006-03-29 | 2007-10-04 | Kowa Co., Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
CN102976996B (en) * | 2009-05-27 | 2015-08-19 | 峡江和美药业有限公司 | Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors |
ES2453477T3 (en) | 2009-12-18 | 2014-04-07 | Frieslandcampina Nederland Holding B.V. | Composition of coprocessed excipient for a tablet, its preparation and use |
CA2784996A1 (en) * | 2009-12-22 | 2011-06-30 | Novartis Ag | Formulation comprising 1 h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
EP2575757A1 (en) | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
EA018867B1 (en) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Method of producing pharmaceutical composition and product therefrom |
CN104825449A (en) * | 2014-02-12 | 2015-08-12 | 天津药物研究院 | Compound composition containing atorvastatin calcium and amlodipine and preparation method of same |
WO2016047749A1 (en) * | 2014-09-26 | 2016-03-31 | 株式会社フジクラ | Optical fiber |
RU2591079C2 (en) * | 2014-12-10 | 2016-07-10 | Александр Владимирович Диковский | Pharmaceutical composition of statins with prebiotic for therapy of hypercholesteremia and hyperlipidemia |
CN107690333B (en) * | 2015-06-10 | 2021-12-17 | 赢创运营有限公司 | Method for preparing powder containing human coagulation factor protein and lactic acid polymer |
US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
CN117835971A (en) | 2021-08-25 | 2024-04-05 | 巴斯夫欧洲公司 | Adjuvant composition for direct compression |
CN114674944A (en) * | 2022-03-04 | 2022-06-28 | 苏州东瑞制药有限公司 | Method for detecting related substances of amlodipine besylate and atorvastatin calcium compound preparation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2392096C (en) * | 1999-11-17 | 2008-07-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20848A (en) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Pharmaceutical formulation containing atorvastatin calcium |
BR0208504A (en) * | 2001-03-27 | 2004-03-09 | Ranbaxy Lab Ltd | Pravastatin Stable Pharmaceutical Composition |
JP2003055217A (en) * | 2001-08-10 | 2003-02-26 | Taiyo Yakuhin Kogyo Kk | Pharmaceutical composition |
GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
BR0317521A (en) * | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
-
2004
- 2004-04-29 CA CA002465693A patent/CA2465693A1/en not_active Abandoned
- 2004-06-01 JP JP2006516511A patent/JP2006527259A/en active Pending
- 2004-06-01 MX MXPA05012955A patent/MXPA05012955A/en unknown
- 2004-06-01 KR KR1020057023718A patent/KR100760112B1/en not_active IP Right Cessation
- 2004-06-01 EP EP04735617A patent/EP1635788A1/en not_active Withdrawn
- 2004-06-01 CN CNA200480016386XA patent/CN1805732A/en active Pending
- 2004-06-01 RU RU2005136743/15A patent/RU2325903C2/en not_active IP Right Cessation
- 2004-06-01 WO PCT/IB2004/001859 patent/WO2004110406A1/en active Application Filing
- 2004-06-01 BR BRPI0411354-3A patent/BRPI0411354A/en not_active IP Right Cessation
- 2004-06-01 AU AU2004246867A patent/AU2004246867A1/en not_active Abandoned
- 2004-06-09 TW TW093116574A patent/TW200503689A/en unknown
- 2004-06-10 AR ARP040102009A patent/AR044660A1/en unknown
-
2005
- 2005-10-11 ZA ZA200508204A patent/ZA200508204B/en unknown
- 2005-12-07 CO CO05124314A patent/CO5640071A2/en unknown
-
2006
- 2006-01-10 NO NO20060149A patent/NO20060149L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0411354A (en) | 2006-07-11 |
MXPA05012955A (en) | 2006-02-13 |
AU2004246867A1 (en) | 2004-12-23 |
ZA200508204B (en) | 2007-03-28 |
CN1805732A (en) | 2006-07-19 |
RU2325903C2 (en) | 2008-06-10 |
WO2004110406A1 (en) | 2004-12-23 |
KR20060025167A (en) | 2006-03-20 |
KR100760112B1 (en) | 2007-09-18 |
CA2465693A1 (en) | 2004-12-12 |
RU2005136743A (en) | 2006-07-27 |
AR044660A1 (en) | 2005-09-21 |
NO20060149L (en) | 2006-03-06 |
JP2006527259A (en) | 2006-11-30 |
EP1635788A1 (en) | 2006-03-22 |
CO5640071A2 (en) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060149L (en) | Pharmaceutical compounds of atorvastatin | |
TW200509905A (en) | Pharmaceutical compositions of atorvastatin | |
AU7031500A (en) | Therapeutic quinazoline compounds | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
EP2305251A3 (en) | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
RS49756B (en) | Use of xenon for preparing a pharmaceutical preparation for treating neurointoxications | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
MXPA02011303A (en) | Liquid pharmaceutical composition containing an erythropoietin derivate. | |
NO20060022L (en) | Stable compositions of atorvastatin prepared by cotton granulation | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
ATE260658T1 (en) | PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION | |
AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
WO2001076638A3 (en) | Compositions for drug delivery | |
AU2207197A (en) | Targeted site specific drug delivery compositions and method of use | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
GB9907571D0 (en) | Compounds | |
EP1031352A3 (en) | Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
MY133682A (en) | Substituted pyrroles | |
WO2002053099A3 (en) | Methods and compositions for treating periodontal disease | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate |